What is primary vitreoretinal lymphoma?
Primary vitreoretinal lymphoma (PVRL) is a rare cancer of the immune system that starts inside the eye. It affects the vitreous, the clear jelly that fills the eyeball, and the retina, the light-sensitive layer at the back of the eye. In most cases it is a type of diffuse large B-cell lymphoma, a fast-growing lymphoma made of abnormal B lymphocytes.
PVRL is considered a form of primary central nervous system lymphoma, because the retina is an extension of the brain. The word “primary” means that, at diagnosis, the lymphoma is found in the eye but not yet in the brain (Soussain et al., 2021).
The main challenge with PVRL is that it can look like inflammation inside the eye (uveitis). People may be treated for uveitis for months before the true cause is found. The disease itself may seem slow at first, but it carries a high risk of later spread to the brain, which is the main threat to life.
How it differs from primary CNS lymphoma of the brain
PVRL belongs to the same family as lymphoma that starts in the brain, described on our page on primary central nervous system lymphoma. The two often occur in the same person, either together or one after the other.
| Feature | Primary CNS lymphoma of the brain | Primary vitreoretinal lymphoma |
|---|---|---|
| First site | Brain, spinal cord or brain fluid | Vitreous and retina of the eye |
| First symptoms | Headache, confusion, weakness, seizures | Floaters and blurred vision |
| Common misdiagnosis | Stroke or other brain tumour | Uveitis |
| Diagnosis | Brain biopsy | Sample of the vitreous |
| Treatment | High-dose methotrexate-based chemotherapy | Eye treatment, often with systemic chemotherapy |
| Link | Some patients also have eye disease | Most patients later develop brain disease |
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Lymphoma, usually diffuse large B-cell type, starting inside the eye |
| How common | Rare; a small fraction of primary CNS lymphomas |
| Typical age | Usually over 50; median in the 60s |
| Eyes affected | Often both eyes, sometimes one after the other |
| Usual first sign | Floaters and blurred vision without pain or redness |
| Main diagnostic test | Vitreous biopsy (vitrectomy) |
| Main treatments | Injections of methotrexate or rituximab into the eye, eye radiotherapy, high-dose methotrexate |
| Main risk | Spread to the brain |
| Outlook | Vision can often be saved; survival depends mainly on brain involvement |
2. Types
Lymphoma inside the eye
| Type | Description |
|---|---|
| Primary vitreoretinal lymphoma | Starts in the vitreous and retina; the subject of this article |
| Vitreoretinal lymphoma with brain involvement | The eye and brain are affected at the same time |
| Secondary vitreoretinal lymphoma | Lymphoma from the brain or elsewhere in the body spreads to the eye |
| Uveal (choroidal) lymphoma | A different disease, usually a slow-growing marginal zone lymphoma in the layer under the retina |
By cell type
| Cell type | Notes |
|---|---|
| Diffuse large B-cell lymphoma | The vast majority |
| T-cell lymphoma | Rare |
3. Causes and risk factors
The cause is not known. Experts think that the lymphoma cells may change outside the eye and then settle and grow in the eye and brain, where the immune system is less active (Soussain et al., 2021).
| Factor | Notes |
|---|---|
| Age | Mostly older adults |
| Weakened immune system | Such as HIV or organ transplant medicines; raises the risk of CNS lymphoma |
| Gene changes in the lymphoma | MYD88 L265P and CD79B changes are common |
| Infections | EBV is linked mainly to lymphoma in people with weak immunity |
| Inherited factors | No inherited cause known |
4. How does it look
On eye examination
| Finding | Description |
|---|---|
| Vitreous cells | Haze or clumps and sheets of cells in the eye jelly |
| Retinal lesions | Creamy-white or yellow spots under the retina |
| “Leopard-skin” pattern | Patchy dark and light spots on the retina |
| Little inflammation | Usually no pain, redness or fluid swelling at the centre of the retina |
| Both eyes | Often affected, though not always to the same degree |
An international consensus noted that a heavy build-up of cells in the vitreous without swelling of the central retina is a typical pattern (Carbonell et al., 2021).
Eye imaging
| Test | Typical findings |
|---|---|
| Optical coherence tomography (OCT) | Bright deposits and bumps under the retina |
| Fundus autofluorescence | Patchy changes in the pigment layer |
| Fluorescein angiography | Spots of abnormal staining in a granular pattern |
Under the microscope
| Feature | Description |
|---|---|
| Lymphoma cells | Large cells with irregular nuclei and little cytoplasm |
| Fragility | The cells break down easily, so samples must be processed quickly |
| Background | Many reactive T cells and debris |
5. Symptoms
Common symptoms
- Floaters: dark spots or threads that drift across vision
- Blurred or cloudy vision
- Symptoms usually come on gradually and are painless
- The eye is often not red
Less common symptoms
| Symptom | Possible cause |
|---|---|
| Loss of central vision | Lymphoma under the retina near the macula |
| Sensitivity to light | Mild inflammation |
| Symptoms in the second eye | Spread to the other eye |
| Headache, confusion, personality change | Spread to the brain |
| Weakness, unsteadiness or seizures | Spread to the brain |
When to seek medical advice
See an eye doctor for new floaters or blurred vision, especially if you are over 50. If you have been treated for uveitis that keeps returning or does not improve with steroids, ask whether lymphoma has been ruled out.
6. Diagnosis
Diagnosis needs close teamwork between eye specialists, pathologists and haematologists.
| Step | What is done |
|---|---|
| Detailed eye examination | Looks for typical vitreous and retinal signs |
| Eye imaging | OCT, autofluorescence and angiography |
| Stop steroids | Steroids should usually be stopped at least two weeks before sampling |
| Diagnostic vitrectomy | Surgery to remove vitreous for testing |
| Cytology and flow cytometry | Look for lymphoma cells and show whether they come from one clone |
| Interleukin levels | Ratio of IL-10 to IL-6 in eye fluid |
| Molecular tests | MYD88 mutation and immunoglobulin gene rearrangement |
| Retinal biopsy | Rarely, if other tests are inconclusive |
Steroids can kill lymphoma cells and make the biopsy negative, which is why they are stopped beforehand (Carbonell et al., 2021).
How accurate are the tests?
A systematic review compared the sensitivity of different tests (Huang et al., 2024).
| Test | Approximate share of PVRL cases detected |
|---|---|
| IL-10 to IL-6 ratio above 1 | About 89% |
| Flow cytometry of vitreous | About 88% |
| Immunoglobulin gene rearrangement | About 85% |
| MYD88 L265P mutation | About 70% |
| CD79B mutation | About 35% |
Because no single test is perfect, doctors usually combine several.
Why diagnosis takes time
Lymphoma cells in the vitreous are few and fragile. Samples must reach the laboratory quickly, and even then the cells may not be recognisable. Steroid drops or tablets given for suspected uveitis can temporarily improve the eye and shrink the lymphoma, which delays the diagnosis further.
Some people need more than one vitrectomy before the diagnosis is confirmed. Your team may combine several laboratory tests on the same sample to make the most of it.
Staging tests
| Test | Purpose |
|---|---|
| MRI of the brain | Looks for brain involvement |
| Lumbar puncture | Checks the brain and spinal fluid for lymphoma cells |
| CT or PET-CT of the body | Rules out lymphoma elsewhere |
| HIV test and blood tests | Assess immunity and fitness for treatment |
7. Treatment
There is no single standard treatment. Plans are based on small studies and expert experience, and should be made by a team that includes an eye specialist and a haematologist or neuro-oncologist.
Treatments for the eye
| Treatment | Details |
|---|---|
| Methotrexate injections into the eye | Given repeatedly over months until the lymphoma clears |
| Rituximab injections into the eye | An antibody against B cells; an alternative or addition |
| Eye radiotherapy | Low-dose radiotherapy to both eyes |
These local treatments usually clear the lymphoma from the eye well, but they do not stop it from appearing later in the brain (Soussain et al., 2021).
Treatments for the whole body
| Treatment | Details |
|---|---|
| High-dose methotrexate | Intravenous chemotherapy that reaches the brain and eye |
| Combination chemotherapy | Methotrexate with other drugs, as for primary CNS lymphoma |
| Intensive chemotherapy with stem cell transplant | Mostly for relapse in fit patients |
A Japanese study of 54 patients found that those who completed high-dose methotrexate after eye injections had a lower risk of brain spread (Motomura et al., 2024).
Treatment of relapse
| Option | Notes |
|---|---|
| Repeat eye injections or radiotherapy | For relapse in the eye |
| Ibrutinib | Tablet that blocks a B-cell signalling pathway |
| Lenalidomide | Tablet that modulates the immune system |
| Temozolomide | Oral chemotherapy |
| High-dose chemotherapy and stem cell transplant | For brain relapse in fit patients |
Side effects
| Treatment | Possible side effects |
|---|---|
| Eye injections | Irritation of the cornea, raised eye pressure, small risk of infection |
| Eye radiotherapy | Dry eye, cataract, rarely retinal damage |
| High-dose methotrexate | Kidney strain, mouth sores, low blood counts; requires hospital stay and monitoring |
| Ibrutinib | Bleeding risk, heart rhythm problems |
| Vitrectomy | Cataract, raised eye pressure, rarely retinal detachment |
8. Outlook (prognosis)
Vision can often be protected or improved with treatment. The main factor for survival is whether the lymphoma spreads to the brain.
| Finding | Details |
|---|---|
| Risk of brain spread | High; about 78% within five years in one Japanese series |
| Five-year survival | About 69% in the same series |
| Factors raising brain risk | Disease in both eyes and a clonal B-cell population on flow cytometry |
| Factor lowering brain risk | Completing systemic high-dose methotrexate |
These figures come from Motomura et al. (2024). Results vary between centres and treatment strategies.
9. Follow-up
| Check | Typical timing |
|---|---|
| Eye examination and OCT | Every 1-3 months at first |
| Brain MRI | Every 3-6 months for the first years |
| Neurological review | At each visit |
| Blood tests | During and after chemotherapy |
Report any new floaters, vision changes, headaches, confusion or weakness straight away.
10. Living with primary vitreoretinal lymphoma
- Keep all eye and brain scan appointments
- Use eye drops as prescribed after injections or surgery
- Do not drive if your vision does not meet legal standards; ask your eye doctor
- Ask about low-vision aids if your sight is affected
- Tell family about symptoms of brain involvement to watch for
- Seek support from lymphoma and sight-loss charities
Coping with vision changes
Losing some sight can affect reading, driving, work and confidence. Eye clinics can refer you to low-vision services, which offer magnifiers, lighting advice and training. Sight-loss charities provide practical tips, emotional support and help with benefits. It is normal to feel anxious about the risk of brain involvement, and talking with your specialist nurse or a counsellor can help.
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is it an eye cancer or a blood cancer? | It is a lymphoma, a cancer of immune cells, that starts inside the eye |
| Why was I first told I had uveitis? | The two conditions look very similar, and lymphoma often hides behind inflammation |
| Will I go blind? | Most people keep useful vision with treatment |
| Will it spread to my brain? | The risk is high, which is why brain scans and sometimes systemic chemotherapy are recommended |
| Are the eye injections painful? | The eye is numbed first; most people feel pressure rather than pain |
| Should I stop my steroid eye drops? | Only on your doctor’s advice; they may be paused before a biopsy |
| Can it be cured? | Some patients stay in long-term remission, especially if the brain is never affected |
12. Questions to ask your care team
- Which tests confirmed the diagnosis?
- Is the lymphoma in one eye or both?
- Has my brain and spinal fluid been checked?
- Do you recommend eye treatment alone or systemic chemotherapy as well?
- How many eye injections will I need?
- What are the signs of brain spread that I should watch for?
- Who should I call if I notice new symptoms between visits?
- Are there clinical trials I could join?
Resources
- Carbonell, D. et al. (2021) ‘Consensus recommendations for the diagnosis of vitreoretinal lymphoma’, Ocular Immunology and Inflammation, 29(3), pp. 507-520.
- Huang, R.S. et al. (2024) ‘Diagnostic methods for primary vitreoretinal lymphoma: a systematic review’, Survey of Ophthalmology, 69(3), pp. 456-464.
- Motomura, Y. et al. (2024) ‘Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma’, British Journal of Haematology, 204(4), pp. 1279-1287.
- Soussain, C., Malaise, D. and Cassoux, N. (2021) ‘Primary vitreoretinal lymphoma: a diagnostic and management challenge’, Blood, 138(17), pp. 1519-1534.
- National Cancer Institute (2026) Primary CNS Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/primary-cns-lymphoma-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.